Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 3/20 | 0.41 |
| ▸ | LITAF | Q99732 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5572451 | 0.85 | STS (0.43) | STSTP53MAPTHDAC1HDAC6 | |
| SCHEMBL5573793 | 0.85 | SMN1; SMN2 (0.44) | STSTP53MAPTHDAC1HDAC6 | |
| SCHEMBL5572456 | 0.84 | STS (0.48) | STSTP53MAPTHDAC1HDAC6 | |
| SCHEMBL4597655 | 0.83 | CCR5 (0.43) | STSTP53MAPTHDAC1HDAC6 | |
| SCHEMBL4609485 | 0.82 | SLC6A2 (0.40) | TP53MAPTHDAC1HDAC6CCR5 | |
| SCHEMBL5576089 | 0.81 | CCR5 (0.54) | STSTP53MAPTCCR5 | |
| SCHEMBL5576084 | 0.81 | CCR5 (0.54) | STSTP53MAPTCCR5 | |
| SCHEMBL4608051 | 0.81 | CCR5 (0.46) | STSTP53MAPTHDAC1HDAC6 | |
| SCHEMBL4625809 | 0.81 | STS (0.45) | STSTP53MAPTHDAC1HDAC6 | |
| SCHEMBL4597776 | 0.80 | TP53 (0.47) | STSTP53MAPTTNFLITAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | STS 4841/4885TP53 2854/4885MAPT 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.